Valeant is getting beat up again

Pharmaceutical firm Valeant’s stock continued its sell off Monday morning with the stock opening down over 5%.

The stock started falling on September 18, when lawmakers started taking action against companies that gouge the prices of prescription drugs. Since then, it’s lost a quarter of its value.

Washington’s interest was peaked when the world found out about Martin Shkreli, a hedge fund manager who purchased a prescription drug and jacked up the price 5,000%.

That started a conversation about pharmaceutical firms that engage in the same behaviour, and Valeant — a Wall Street darling with a connection to hedge fund manager Bill Ackman — was pinpointed as one of the worst offenders.

Last week, short selling firm Citron research released a note about Valeant with a table listing all the drugs the company purchased and their price increases:

NOW WATCH: We got our hands on Donald Trump’s failed 1989 board game and it’s bizarre

NOW WATCH: Money & Markets videos

Want to read a more in-depth view on the trends influencing Australian business and the global economy? BI / Research is designed to help executives and industry leaders understand the major challenges and opportunities for industry, technology, strategy and the economy in the future. Sign up for free at research.businessinsider.com.au.